Get the Stockscreener App
190.46
0.25%
0.47
After Hours:
190.50
0.04
+0.02%
Revolution Medicines Inc stock is traded at $190.46, with a volume of 1.89M.
It is up +0.25% in the last 24 hours and up +27.63% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
See More
Previous Close:
$189.99
Open:
$189.65
24h Volume:
1.89M
Relative Volume:
0.56
Market Cap:
$40.49B
Revenue:
$742.00K
Net Income/Loss:
$-1.37B
P/E Ratio:
-26.93
EPS:
-7.0731
Net Cash Flow:
$-1.07B
1W Performance:
+1.70%
1M Performance:
+27.63%
6M Performance:
+85.43%
1Y Performance:
+419.39%
1-Day Range:
$186.56
$192.92
1-Week Range:
$182.82
$193.69
52-Week Range:
$34.00
$193.69
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
650-481-6801
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Feb-27-26 | Resumed | UBS | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Revolution Medicines (RVMD) Holds Steady Near Resistance—Consolidation or Catalyst Ahead?Vol Target Rebalance - dars.gov.et
Revolution Medicines Says EMA Begins Phased Review of Daraxonrasib for Pancreatic Cancer as FDA NDA Submission Nears Completion - Quiver Quantitative
EMA fast-tracks Revolution Medicines' pancreatic cancer drug review - Stock Titan
Revolution Medicines wins EU fast track review (RVMD:NASDAQ) - Seeking Alpha
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill - Reuters
There's a Revolution in Cancer. But Can Big Pharma Afford It? -- Heard on the Street -- WSJ - Moomoo
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More - The Motley Fool
Revolution Medicines stock hits all-time high at 193.12 USD By Investing.com - Investing.com South Africa
RVMD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $195 - GuruFocus
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Revolution Medicines stock hits all-time high at 193.12 USD - Investing.com
RVMD Maintained by Mizuho -- Price Target Raised to $215 - GuruFocus
Mizuho Raises Price Target on Revolution Medicines to $215 From $185, Keeps Outperform Rating - Moomoo
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy? - The Motley Fool
Revolution Medicines, Inc. Warrant Financial Disclosures & SEC Filings - TradingView
Why Revolution Medicines (RVMD) Is Up 6.2% After Early Zoldonrasib Pancreatic Cancer Data And What's Next - Yahoo Finance
Revolution Medicines (RVMD) Reports Positive Zoldonrasib Trial Data Ahead Of Phase 3 - Yahoo Finance
RVMDRevolution Medicines Inc Latest SEC Filings - Finviz
Revolution Medicines sees large block trade worth $196.7 million By Investing.com - Investing.com Canada
Revolution Medicines director Sushil Patel sells $1.05m in stock By Investing.com - Investing.com Australia
Revolution Medicines sees large block trade worth $196.7 million - Investing.com
LifeSci Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $263 - Moomoo
Revolution Medicines reports zoldonrasib pancreatic cancer data - grafa.com
Revolution Medicines reports trial results for pancreatic cancer drug - Investing.com
Revolution Medicines reports trial results for pancreatic cancer drug By Investing.com - Investing.com South Africa
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 - The Manila Times
Revolution Medicines Presents Phase 1/2 Clinical Data for - GlobeNewswire
Revolution Medicines director Sushil Patel sells $1.05m in stock - Investing.com
Form 4 Revolution Medicines Inc For: 1 July By Investing.com - Investing.com UK
Revolution Medicines (NASDAQ: RVMD) director sells 5,580 shares, exercises options - Stock Titan
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd. - The Motley Fool
Price to sales forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Price to earnings forward of Revolution Medicines, Inc. – BMV:RVMD - TradingView
8-Day Rally Sends Revolution Medicines Stock Up 23% - Trefis
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Price to earnings forward of Revolution Medicines, Inc. – NASDAQ:RVMD - TradingView
Price to earnings forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Revolution Medicines Price Target Raised to $235.00/Share From $183.00 by Needham - Moomoo
Revolution Medicines, Inc.(NasdaqGS:RVMD) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Proposed sale of RVMD common shares reported (NASDAQ: RVMD) - Stock Titan
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - StreetInsider
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell Midcap Growth Benchmark - marketscreener.com
Price to sales forward of Revolution Medicines, Inc. – MIL:1RVMD - TradingView
RVMD Maintained by Needham -- Price Target Raised to $235 - GuruFocus
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces - GlobeNewswire
Revolution Medicines Is Maintained at Buy by Needham - Moomoo
Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $215 - Moomoo
Revolution Medicines, Inc. (RVMD) Stock Analysis: Unraveling A $38.71 Billion Biotechnology Powerhouse's Growth Potential - DirectorsTalk Interviews
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.73%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):